Indication

Pemphigus vulgaris

Pemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age. Read more about Pemphigus vulgaris

3 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Pemphigus vulgaris therapies.

Showing 1–3 of 3 drugs

RITUXAN (rituximab)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA·+10
GENENTECH

RUXIENCE (rituximab-pvvr)

ANTINEOPLASTIC MONOCLONAL ANTIBODIES·RELAPSE OR REFRACTORY NON-HODGKIN'S LYMPHOMA·+7
Parke-Davis Pfizer
Filter & compare in the drug finder →Opens the drug finder with Pemphigus vulgaris preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Pemphigus vulgaris.

Pemphigus vulgaris is a rare, severe, chronic autoimmune mucocutaneous disorder that primarily affects adults between 40 and 60 years of age.

Pathophysiologically, it is characterized by pathogenic immunoglobulin G autoantibodies directed against desmoglein 3 and often desmoglein 1, which are critical cadherin proteins responsible for intercellular adhesion between keratinocytes.

This antibody-mediated disruption triggers intraepidermal acantholysis, resulting in widespread loss of cell-cell adhesion.

Clinically, the disease presents with extremely fragile, flaccid bullae and painful, non-healing erosions that typically initiate in the oral mucosa before progressing to involve the skin and other mucous membranes.

Personalize your experience

Follow Pemphigus vulgaris and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it